Ignite Creation Date:
2025-12-24 @ 6:56 PM
Ignite Modification Date:
2026-05-14 @ 12:39 AM
Study NCT ID:
NCT01034657
Status:
TERMINATED
Last Update Posted:
2017-08-11
First Post:
2009-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myelodysplastic Syndrome (MDS) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | MDS | View |
| None | bone marrow | View |
| None | anemia | View |
| None | cytopenia | View |
| None | transfusion dependance | View |
| None | EPO | View |
| None | ESA | View |
| None | erythropoietin | View |
| None | LBH589 | View |
| None | Myelodysplastic Syndromes | View |
| None | hematopoietic improvement | View |
| None | IPSS Low | View |
| None | IPSS Int-1 | View |
| None | HI-E | View |
| None | HDAC Inhibitor | View |
| None | HDAC-I | View |
| None | DAC-I | View |
| None | Deacetylase-Inhibitor | View |
| None | Histone Deacetylase-Inhibitor | View |
| None | red blood cell transfusions | View |